Abstract
Background: Transforming growth factor beta (TGF-β) is a multifunctional protein that acts as a regulator of cellular function such as proliferation, migration, differentiation, apoptosis, vascular hemostasis, and development of organisms. As the TGF-β is the key player of cell proliferation and apoptosis it also involves in different diseases such as autoimmune disorder and vascular disease. The TGF-β signaling pathway starts with the activation of TGFBRII and TGFBRI that trigger the phosphorylation of Smad cascade. The Smads complexes (Smad4+R-Smad) translocate to the nucleus and induce the transcription of the target gene. The dysregulation of the TGF-β signaling pathways has been reported in many human diseases including cancer. TGF-β acts as a tumor suppressor in the early stage of cancer but in late-stage show oncogenic factor and loss antiproliferative response.
Objective: This reviews article determines the mechanism of TGF-β signaling pathways, the effect of TGF-β component on different cancers and provides a brief overview how it (TGF-β) acts as a tumor suppressor and promoter.
Conclusion:TGF-β signaling pathways have a multifaceted and fundamental role in human development. It acts as a double-edged sword, both tumor suppressor, and tumor promoter. The tumor suppressor role is commonly designated as antiproliferative and apoptotic effects. TGF-β stops cell cycle at the G1 phase and promotes apoptosis. However, in advance stage of the tumor, it lost suppressor activities and begin tumor promotor due to the mutation in some component of the TGF-β pathway. Thus, The TGF-β can no longer control the cell cycle and proliferate the cancer cell. The increased production of TGF-β induces tumor invasion, motility, metastasis, immunosuppression epithelial-to-mesenchymal transition and angiogenesis. To study the exact molecular mechanism of TGF-β in the cancer cell and determine the oncogenic activities can provide successful and new therapeutic approach to reestablish the ordinary function of TGF-β.
Keywords: Transforming growth factor beta, apoptosis, hemostasis, cancers, nucleus, carcinogenesis.
Graphical Abstract
Current Signal Transduction Therapy
Title:Positive and Negative Effects of TGF-β Signaling Pathways in Carcinogenesis
Volume: 12 Issue: 2
Author(s): Irfan Ullah*Liling Tang
Affiliation:
- Key Laboratory of Bio Rheological Science and Technology, Ministry of Education, College of Bioengineering Chongqing University, Chongqing 400044,China
Keywords: Transforming growth factor beta, apoptosis, hemostasis, cancers, nucleus, carcinogenesis.
Abstract: Background: Transforming growth factor beta (TGF-β) is a multifunctional protein that acts as a regulator of cellular function such as proliferation, migration, differentiation, apoptosis, vascular hemostasis, and development of organisms. As the TGF-β is the key player of cell proliferation and apoptosis it also involves in different diseases such as autoimmune disorder and vascular disease. The TGF-β signaling pathway starts with the activation of TGFBRII and TGFBRI that trigger the phosphorylation of Smad cascade. The Smads complexes (Smad4+R-Smad) translocate to the nucleus and induce the transcription of the target gene. The dysregulation of the TGF-β signaling pathways has been reported in many human diseases including cancer. TGF-β acts as a tumor suppressor in the early stage of cancer but in late-stage show oncogenic factor and loss antiproliferative response.
Objective: This reviews article determines the mechanism of TGF-β signaling pathways, the effect of TGF-β component on different cancers and provides a brief overview how it (TGF-β) acts as a tumor suppressor and promoter.
Conclusion:TGF-β signaling pathways have a multifaceted and fundamental role in human development. It acts as a double-edged sword, both tumor suppressor, and tumor promoter. The tumor suppressor role is commonly designated as antiproliferative and apoptotic effects. TGF-β stops cell cycle at the G1 phase and promotes apoptosis. However, in advance stage of the tumor, it lost suppressor activities and begin tumor promotor due to the mutation in some component of the TGF-β pathway. Thus, The TGF-β can no longer control the cell cycle and proliferate the cancer cell. The increased production of TGF-β induces tumor invasion, motility, metastasis, immunosuppression epithelial-to-mesenchymal transition and angiogenesis. To study the exact molecular mechanism of TGF-β in the cancer cell and determine the oncogenic activities can provide successful and new therapeutic approach to reestablish the ordinary function of TGF-β.
Export Options
About this article
Cite this article as:
Ullah Irfan *, Tang Liling , Positive and Negative Effects of TGF-β Signaling Pathways in Carcinogenesis, Current Signal Transduction Therapy 2017; 12 (2) . https://dx.doi.org/10.2174/1574362412666171003160732
DOI https://dx.doi.org/10.2174/1574362412666171003160732 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Determinants of Paraoxonase 1 Status: Genes, Drugs and Nutrition
Current Medicinal Chemistry Resurgence of Herbal Antihypertensives in Management of Hypertension
Current Hypertension Reviews Therapeutic Progress and Knowledge Basis on the Natriuretic Peptide System in Heart Failure
Current Topics in Medicinal Chemistry Relationship between Hyperlipidemia, Cardiovascular Disease and Stroke: A Systematic Review
Current Cardiology Reviews Auto-Antibodies As Possible Markers and Mediators of Ischemic, Dilated, and Rhythmic Cardiopathies
Current Drug Targets The Inhibitory Effect of Some Algerian Plants Phenolics Extracts on the α - glucosidase and α - amylase Activities and their Antioxidant Activities
Current Enzyme Inhibition Fospropofol, A New Sedative Anesthetic, and Its Utility in the Perioperative Period
Current Pharmaceutical Design A Review of Therapeutic Effects of Curcumin
Current Pharmaceutical Design The Mineralocorticoid Receptor in Endothelial Physiology and Disease: Novel Concepts in the Understanding of Erectile Dysfunction
Current Pharmaceutical Design Gene Therapy for Familial Hypercholesterolemia
Current Pharmaceutical Design 1h Post-load Blood Glucose in the Identification of Proatherogenic Cardiometabolic Profile in Obesity
Endocrine, Metabolic & Immune Disorders - Drug Targets Hypertension in China: Past, Present, and Future
Current Hypertension Reviews Inpatient Care of the HIV Infected Patient in the Highly Active Antiretroviral Therapy (HAART) Era
Current HIV Research The Impact of Substance P on the Pathogenesis of Insulin Resistance Leading to Gestational Diabetes
Current Pharmaceutical Biotechnology Moving to the Rhythm with Clock (Circadian) Genes, Autophagy, mTOR, and SIRT1 in Degenerative Disease and Cancer
Current Neurovascular Research Molecular Mechanisms of Inflammation. Anti-Inflammatory Benefits of Virgin Olive Oil and the Phenolic Compound Oleocanthal
Current Pharmaceutical Design Propitious Profile of Peppery Piperine
Current Molecular Pharmacology Endothelial Function: A Surrogate Endpoint in Cardiovascular Studies?
Current Pharmaceutical Design Editorial (Novel Therapies and Botanical and Mechanical Approaches for Management of Cardiovascular Disease)
Recent Patents on Cardiovascular Drug Discovery 58-Year Old Men with Non-Stenotic Carotid Artery Plaques and the Relationship with Cardiovascular Risk Factors and Future Cardiovascular Events
Vascular Disease Prevention (Discontinued)